19 Jul 2022 Sequana Medical completes enrollment in Phase 2a SAHARA I DSR study and reports disease-modifying profile for Short Term DSR Member news
05 Jul 2022 ANeuroTech receives positive feedback from the FDA for its pivotal Phase IIIb development programme for ANT-01 as an adjunctive anti-depression drug for Major Depressive Disorder Member news
28 Jun 2022 MRM Health starts clinical trial with next-generation optimized consortium therapeutic MH002 in Pouchitis Member news
10 May 2022 UCB presents efficacy and safety results for zilucoplan and rozanolixizumab in generalized myasthenia gravis Member news
09 May 2022 Oxurion announces top-line results from Part A of Phase 2 INTEGRAL trial evaluating THR-687 for treatment of diabetic macular edema (DME) Member news
05 May 2022 argenx announces positive Phase 3 data from ADVANCE trial of VYVGART® (efgartigimod alfa-fcab) in adults with primary immune thrombocytopenia Member news
03 May 2022 reMYND’s novel Alzheimer program reports excellent brain exposure and safety profile in Phase 1; transitioning into Phase 2a Member news
14 Apr 2022 Mithra announces improved consolidated topline results from Donesta® Phase 3 studies and launch of recruitment for the extension of European study Member news
05 Apr 2022 Sequana Medical announces the completion of alfapump implantations in POSEIDON, the North American pivotal alfapump study Member news
05 Apr 2022 Aligos Therapeutics selects drug candidate ALG-097558, a potent ritonavir-free oral protease inhibitor for the treatment and prevention of COVID-19 Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
